Patents by Inventor Manmohan Reddy Leleti

Manmohan Reddy Leleti has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROCESSES FOR PREPARING AMINOPYRIMIDINE COMPOUNDS
    Publication number: 20220235031
    Abstract: Provided herein are improved processes for preparing aminopyrimidine compounds of Formula (I). The disclosed processes advantageously proceed through a ?-diketoester intermediate of Formula (A) and avoid the direct linking of a pyrimidine and phenyl moieties. The disclosed methods significantly increase yield of the desired compounds and simplifies the synthetic route.
    Type: Application
    Filed: June 5, 2020
    Publication date: July 28, 2022
    Inventors: Manmohan Reddy LELETI, Dillon Harding MILES, Brandon Reid ROSEN, Ehesan Ul SHARIF, Jay Patrick POWERS
  • CAPSULE FORMULATIONS
    Publication number: 20220233453
    Abstract: The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.
    Type: Application
    Filed: December 8, 2021
    Publication date: July 28, 2022
    Inventors: Manmohan Reddy LELETI, Jay P. POWERS
  • SUBSTITUTED ANILINES AS CCR(4) ANTAGONISTS
    Publication number: 20220194929
    Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
    Type: Application
    Filed: September 9, 2021
    Publication date: June 23, 2022
    Inventors: Trevor T. CHARVAT, Junfa FAN, Christopher W. LANGE, Manmohan Reddy LELETI, Yandong LI, Venkat Reddy MALI, Jeffrey P. McMAHON, Jay POWERS, Sreenivas PUNNA, Ju YANG
  • AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20220144808
    Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: October 22, 2021
    Publication date: May 12, 2022
    Inventors: Joel BEATTY, Laurent DEBIEN, Jenna JEFFREY, Manmohan Reddy LELETI, Debashis MANDAL, Dillon MILES, Jay POWERS, Brandon ROSEN, Ehesan SHARIF, Rhiannon THOMAS-TRAN
  • Inhibitors of CD73-mediated immunosuppression
    Patent number: 11267845
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: November 17, 2017
    Date of Patent: March 8, 2022
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Ehesan Ul Sharif
  • INHIBITORS OF ARG1 AND/OR ARG2
    Publication number: 20220016143
    Abstract: Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.
    Type: Application
    Filed: November 15, 2019
    Publication date: January 20, 2022
    Inventors: Joel BEATTY, Eric Thomas NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Corinne Nicole FOLEY, Rebecca Louise GRANGE, Tezcan GUNEY, Steven Donald JACOB, Jaroslaw KALISIAK, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL
  • MODULATORS OF CHEMOKINE RECEPTORS
    Publication number: 20220009912
    Abstract: Compounds are provided as chemokine inhibitors having the structure:
    Type: Application
    Filed: March 4, 2021
    Publication date: January 13, 2022
    Inventors: Xi CHEN, Dean R. DRAGOLI, Junfa FAN, Jaroslaw KALISIAK, Antoni KRASINSKI, Manmohan Reddy LELETI, Venkat MALI, Jeffrey McMAHON, Rajinder SINGH, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG
  • INHIBITORS OF CXCR2
    Publication number: 20220009911
    Abstract: Compounds are provided as inhibitors of CXCR2, having the structure:
    Type: Application
    Filed: April 29, 2021
    Publication date: January 13, 2022
    Inventors: Xi CHEN, Dean R. DRAGOLI, Junfa FAN, Jaroslaw KALISIAK, Manmohan Reddy LELETI, Viengkham MALATHONG, Jeffrey McMAHON, Hiroko TANAKA, Ju YANG, Chao YU, Penglie ZHANG, Venkat MALI
  • Quinazoline-pyrazole derivatives for the treatment of cancer-related disorders
    Patent number: 11220492
    Abstract: A compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors having Formula (I) and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: May 16, 2018
    Date of Patent: January 11, 2022
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Manmohan Reddy Leleti, Dillon Harding Miles, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • MODULATORS OF 5'-NUCLEOTIDASE, ECTO AND THE USE THEREOF
    Publication number: 20210371449
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: March 19, 2021
    Publication date: December 2, 2021
    Inventors: Laurent Pierre Paul DEBIEN, Juan Carlos JAEN, Jaroslaw KALISIAK, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Dillon Harding MILES, Eric NEWCOMB, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • CD73 INHIBITORS
    Publication number: 20210346353
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Application
    Filed: August 26, 2019
    Publication date: November 11, 2021
    Inventors: Joel BEATTY, Laurent Pierre Paul DEBIEN, Samuel Lawrie DREW, Jeremy FOURNIER, Rebecca Louise GRANGE, Steven Donald JACOB, Jenna Leigh JEFFREY, Kenneth V. LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Debashis MANDAL, Jay Patrick POWERS, Anh Thu TRAN, Rhiannon THOMAS-TRAN, Xuelei YAN
  • TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA
    Publication number: 20210317079
    Abstract: Compounds that inhibit HIF-2?, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2?.
    Type: Application
    Filed: March 18, 2021
    Publication date: October 14, 2021
    Inventors: Joel Worley BEATTY, Samuel Lawrie DREW, Matthew EPPLIN, Jeremy Thomas Andre FOURNIER, Balint GAL, Tezcan GUNEY, Karl T. HAELSIG, Clayton HARDMAN, Steven Donald JACOB, Jenna Leigh JEFFREY, Jaroslaw KALISIAK, Kenneth Victor LAWSON, Manmohan Reddy LELETI, Erick Allen LINDSEY, Artur Karenovich MAILYAN, Debashis MANDAL, Guillaume MATA, Hyunyoung MOON, Jay Patrick POWERS, Brandon Reid ROSEN, Yongli SU, Anh Thu TRAN, Zhang WANG, Xuelei YAN, Kai YU
  • Substituted anilines as CCR(4) antagonists
    Patent number: 11142521
    Abstract: Aniline compounds are provided which bind to CCR(4) and are useful for the treatment of diseases such as allergic diseases, autoimmune diseases, graft rejection and cancer.
    Type: Grant
    Filed: July 30, 2019
    Date of Patent: October 12, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Trevor T. Charvat, Junfa Fan, Christopher W. Lange, Manmohan Reddy Leleti, Yandong Li, Venkat Reddy Mali, Jeffrey P. McMahon, Jay Powers, Sreenivas Punna, Ju Yang
  • C5AR ANTAGONISTS
    Publication number: 20210269398
    Abstract: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.
    Type: Application
    Filed: October 20, 2020
    Publication date: September 2, 2021
    Inventors: Pingchen Fan, Kevin Lloyd Greenman, Manmohan Reddy Leleti, Yandong Li, Jay Powers, Hiroko Tanaka, Ju Yang, Yibin Zeng
  • SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
    Publication number: 20210269422
    Abstract: The present invention provides solid forms, solvates and hydrates of 3-[2-amino-6-(1-{[6-(2-hydroxypropan-2-yl)pyridine-2-yl]methyl}-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl]-2-methylbenzonitrile, and methods of making and using the same.
    Type: Application
    Filed: July 17, 2019
    Publication date: September 2, 2021
    Inventors: Jenna Leigh Jeffrey, Manmohan Reddy Leleti, Dillon Harding Miles, Jay Patrick Powers
  • Azolopyrimidine for the treatment of cancer-related disorders
    Patent number: 11072597
    Abstract: Compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: July 27, 2021
    Inventors: Joel Beatty, Laurent Debien, Jenna Jeffrey, Manmohan Reddy Leleti, Debashis Mandal, Dillon Miles, Jay Powers, Brandon Rosen, Ehesan Sharif, Rhiannon Thomas-Tran
  • QUINAZOLINE-PYRAZOLE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
    Publication number: 20210214346
    Abstract: A compound that is an inhibitor of at least one of the A2A and A2B adenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Application
    Filed: May 16, 2018
    Publication date: July 15, 2021
    Inventors: Manmohan Reddy LELETI, Dillon Harding MILES, Jay Patrick POWERS, Brandon Reid ROSEN, Ehesan Ul SHARIF
  • Inhibitors of adenosine 5?-nucleotidase
    Patent number: 11058704
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: October 2, 2017
    Date of Patent: July 13, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
    Patent number: 11045472
    Abstract: Compounds of Formula I that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing compounds of Formula I and methods for synthesizing compounds of Formula I, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.
    Type: Grant
    Filed: May 3, 2018
    Date of Patent: June 29, 2021
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Manmohan Reddy Leleti, Dillon Harding Miles, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif, Rhiannon Thomas-Tran
  • Inhibitors of CXCR2
    Patent number: 11040960
    Abstract: Compounds are provided as inhibitors of CXCR2, having the structure:
    Type: Grant
    Filed: June 12, 2019
    Date of Patent: June 22, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Xi Chen, Dean R. Dragoli, Junfa Fan, Jaroslaw Kalisiak, Manmohan Reddy Leleti, Viengkham Malathong, Jeffrey McMahon, Hiroko Tanaka, Ju Yang, Chao Yu, Penglie Zhang, Venkat Mali